Last reviewed · How we verify
Long acting insulin
Long acting insulin is a Long-acting insulin Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: Glargine.
Long-acting insulin provides sustained glucose control by mimicking the body's basal insulin secretion over an extended period.
Long-acting insulin provides sustained glucose control by mimicking the body's basal insulin secretion over an extended period. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Long acting insulin |
|---|---|
| Also known as | Glargine |
| Sponsor | Ain Shams University |
| Drug class | Long-acting insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Long-acting insulins are designed to be absorbed slowly and provide steady insulin levels for approximately 24 hours or longer, reducing the need for multiple daily injections. They work by binding to insulin receptors on muscle and fat cells, facilitating glucose uptake and storage, thereby maintaining stable blood glucose levels throughout the day and night.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (PHASE2)
- Effect of Topical Insulin on Healing Rate of Pemphigus Lesions (PHASE2)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (PHASE3)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Long acting insulin CI brief — competitive landscape report
- Long acting insulin updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Long acting insulin
What is Long acting insulin?
How does Long acting insulin work?
What is Long acting insulin used for?
Who makes Long acting insulin?
Is Long acting insulin also known as anything else?
What drug class is Long acting insulin in?
What development phase is Long acting insulin in?
What are the side effects of Long acting insulin?
What does Long acting insulin target?
Related
- Drug class: All Long-acting insulin drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Glargine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing